Health advocates and patients are urging the UK government to expand access to routine prostate cancer screening, following a recommendation against targeted testing from the Health Secretary’s advisory committee. The decision has renewed concerns among survivors and clinicians who argue that earlier detection could save thousands of lives each year.
Prostate cancer is the most common cancer in British men, and early disease often causes no symptoms. Supporters of screening say this makes proactive testing essential.
Survivors Cite Missed Diagnoses and Delayed Testing
Several men who wrote to national media outlets this week described how prostate-specific antigen (PSA) testing led to life-saving diagnoses—sometimes despite initial resistance from clinicians.
One survivor reported having no symptoms and no known risk factors when he independently sought a PSA test through a community organization. Elevated results triggered MRI and CT imaging and a biopsy confirming prostate cancer. He underwent surgery and remains cancer-free one year later. He argued that concerns about overdiagnosis and treatment-related side effects should not outweigh the potential to “save up to 12,000 lives a year.”
Another man shared a decade-long delay in diagnosis after three general practitioners discouraged PSA testing, citing concerns about test accuracy. When a PSA test was finally performed at age 70, his level measured 98—far above the expected value of about 7 for his age. He was diagnosed with stage 3 prostate cancer and credits subsequent hormone therapy and radiotherapy for his survival 11 years later. He said clinicians performing his biopsy supported PSA testing every two years for men over 50.
Clinicians Voice Caution but Acknowledge Evolving Evidence
Some physicians remain concerned about the potential harms of widespread screening. Overtreatment can lead to complications such as urinary incontinence, erectile dysfunction, and psychological distress. A general practitioner responding to the public debate warned of the “compensation implications” for men harmed by investigations later deemed unnecessary, emphasizing the need for balanced, evidence-based decision-making.
Other clinicians questioned whether specialists regularly test their own PSA levels, highlighting ongoing professional disagreement about best practices.
National Policy Remains Divided
The advisory committee’s position reflects long-standing concerns about false positives and the risk of diagnosing slow-growing cancers that may never cause harm. However, critics argue that improved imaging technology and updated risk-stratification tools now allow for more accurate diagnosis and more selective treatment.
Advocates are pressing for a screening program similar to those used for breast and colorectal cancer—structured, regularly offered, and paired with clear guidance on risks and benefits. The Health Secretary has not announced whether the decision will be revisited.
Related topics
Experts Urge Early Screening Because Prostate Cancer Symptoms Often Appear Very Late
Experts Divided As UK Panel Rejects Routine Prostate Cancer Screening
Male Infertility Often Overlooked, Forcing Couples Into Unnecessary IVF, Experts Warn
